China
Africa
Explore chapters and articles related to this topic
Ertapenem
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Pilar Retamar, Luis-Eduardo López-Cortés
Ertapenem is indicated for the treatment of severe, complicated urinary tract infections (cUTIs), particularly in cases at risk of having resistant Gram-negative pathogens and as part of directed therapy in cases with isolates demonstrating the presence of ESBLs and/or fluoroquinolone-resistant microorganisms (see Table 40.10).
Proctocolectomy for Inflammatory Bowel Disease Laparoscopic
Published in P Ronan O’Connell, Robert D Madoff, Stanley M Goldberg, Michael J Solomon, Norman S Williams, Operative Surgery of the Colon, Rectum and Anus Operative Surgery of the Colon, Rectum and Anus, 2015
Guidelines of the National Surgical Quality Improvement Program (NSQIP) are followed. Ertapenem 1 g i.v. is administered within 60 minutes prior to the incision in patients without a penicillin allergy. No postoperative dosesare required secondary to the 24-hour duration of action. Metronidazole 1 g i.v. and ciprofloxacin 500 mg i.v. are used in combination in the patient allergic to penicillin. A warming blanket is used preoperatively and during the induction of anesthesia for the maintenance of normothermia.
The Carbapenems
Published in Thomas T. Yoshikawa, Shobita Rajagopalan, Antibiotic Therapy for Geriatric Patients, 2005
Ertapenem is available in 1 g vials for preparation of IV and intramuscular doses. Doses fdr intramuscular administration should be reconstituted with 1% lidocaine to reduce the pain of injection. The usual dosage is 1 g once daily. Dosage adjustment is recommended when creatinine clearance is 30mL/min or less. If ertapenem is administered within 6 hr of a hemodialysis session, a supplemental 150mg dose should be administered at the end of dialysis (15).
Retrospective evaluation of the patients with urinary tract infections due to carbapenemase producing Enterobacteriaceae
Published in Journal of Chemotherapy, 2020
Uğur Önal, Oğuz Reşat Sipahi, Hüsnü Pullukçu, Tansu Yamazhan, Bilgin Arda, Sercan Ulusoy, Şöhret Aydemir, Meltem Işıkgöz Taşbakan
In a multicenter study from United States of America, a total number of 266 hospital’s data were analysed and fluoroquinolone usage was reported to be a significant risk factor for CRE infections (p = 0.0007) in contrast to carbapenem usage.10 In our study, history of fluoroquinolone usage rate was 49.3% and carbapenem usage was 46.5%. In addition to this, history of ertapenem usage was found as a risk factor for mortality (p = 0.067) in contrast to history of meropenem usage (p = 0.454). Especially in recent years, the term of ‘colleteral damage’ appears as an important healthcare problem due to unnecessary usage of the antibiotics and the selection of multidrug antibiotic-resistant pathogens. Although the fluoroquinolones were the usual suspects for colleteral damage, we found that the history of ertapenem usage as a risk factor for mortality. Thus, we believe that unnecessary usage of ertapenem should be avoided and indications for ertapenem treatment should be carefully determined.
Ertapenem-associated neurotoxicity in the spinal cord injury (SCI) population: A case series
Published in The Journal of Spinal Cord Medicine, 2018
Ursula C. Patel, Mallory A. Fowler
Ertapenem is a broad spectrum carbapenem antibiotic with activity against Gram-positive and Gram-negative organisms. Pharmacokinetic properties unique to ertapenem include high protein binding caused by increased lipophilicity and a net negative charge, which provides a long half-life and allows for once daily dosing.1 Indications for use include a variety of infections such as complicated urinary tract, intra-abdominal, and skin and skin structure infections.2 Its stability against hydrolysis by extended spectrum beta-lactamases (ESBL) allows it to be at the forefront of treatment for many multi-drug resistant (MDR) organisms, particularly in the Enterobacteriaceae group.1,2 Though all hospitalized patients can be susceptible to MDR infections, the Spinal Cord Injury (SCI) patient population, in particular, are at risk due to underlying disease pathology leading to an increased prevalence of invasive interventions such as urinary catheterization and mechanical ventilation, as well as frequent utilization of the healthcare system.3,4 Although neurotoxicity including seizures due to ertapenem is a known adverse effect and has been described previously,5 other manifestations such as delirium and visual hallucinations have rarely been reported;6–14 and no literature, to the best of our knowledge, exists specifically describing these effects solely in the SCI population. We describe 4 cases of mental status changes and hallucinations in SCI patients attributed to ertapenem therapy.
Unconventional therapies for hidradenitis suppurativa
Published in Expert Review of Clinical Pharmacology, 2018
Claudio Marasca, Maria Carmela Annunziata, Maddalena Napolitano, Gabriella Fabbrocini
A prospective study investigated an innovative approach based on 6 weeks of ertapenem (1 g daily) with subsequent rifampicin (10 mg/kg once daily), moxifloxacin (400 mg once daily), and metronidazole (500 mg; three times daily) combination treatment for 6 weeks, further followed by rifampicin (10 mg/kg once daily) and moxifloxacin alone (400 mg once daily) for 6 weeks. This kind of therapy showed significative improvement [32]. Braunberger et al. conducted a retrospective chart review and telephone interview in order to evaluate the efficacy of intravenous ertapenem in patients affected by recalcitrant form of HS. Questions relating to satisfaction, quality of life changes, and disease state changes with ertapenem therapy were asked to the patients. Almost all experienced a good clinical outcome as well as a great satisfaction with ertapenem treatment [33]. However, ertapenem efficacy is still controversy, due to the required long-term intravenous administration of an expensive antibiotic [34].